CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has worked diligently but unsuccessfully to produce an one-time therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is actually an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as a combination treatment in the therapy of multi-drug-resistant HIV are actually closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my last few shares. The first CytoDyn post of mine, “CytoDyn: What In order to Do When It’s Too Good To Be True?”, set out the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a highly marketing picture in the Uptick Newswire job interview which I came away with a bad impression of the company.

Irony of irony, my bad opinion of the business has grown steadily, though the disappointment has not been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger yet still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much-storied treatment (which I shall mean as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the treatment as well as prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s payment of $3.5 huge number of transfers ownership of this technology and also connected intellectual property coming from Progenics to CytoDyn, and roughly 25 million mg of majority drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 million) as well as the first new drug program endorsement ($five million), and also royalty payments of 5 percent of net sales after commercialization.

Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to acquire a sector cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and multiple therapies, it has this single therapy as well as a “broad pipeline of indications” because it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely beneficial therapy in dozens of indications.

The opening banner of its on its website (below) shows an energetic company with diverse interests albeit centered on leronlimab, multiple disease types, multiple publications and multiple delivering presentations.

Can it all be smoke cigarettes and mirrors? That is a question I have been asking myself from the very start of the interest of mine in this particular business. Judging by the multiples of thousands of diverse responses on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this question.

CytoDyn is a traditional battleground, or possibly some might say cult inventory. Its adherents are fiercely protective of its prospects, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News